At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01541 IMMUNEONCO-B
Trading 02-26 13:38:24
4.200
-0.160
-3.67%
High4.470Low4.200Vol454.60K
Open4.330D1 Closing4.360Amplitude6.19%
Mkt Cap1.81BTradable Cap1.77BTotal Shares432.00M
T/O1.97MT/O Rate0.11%Tradable Shares420.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
IMMUNEONCO-B (01541) Grants Loan with Principal Amount of 13.7247 Million Yuan
Stock News  ·  02-10
IMMUNEONCO-B (01541) Grants Loan with Principal Amount of 13.7247 Million Yuan
ImmuneOnco Biopharmaceuticals Grants RMB13.7 Million Loan to Executive Chairman
Reuters  ·  02-10
ImmuneOnco Biopharmaceuticals Grants RMB13.7 Million Loan to Executive Chairman
ImmuneOnco Biopharmaceuticals Shanghai Inc - to Make Available to CEO Loan in Principal Amount of RMB13.7 Mln
THOMSON REUTERS  ·  02-10
ImmuneOnco Biopharmaceuticals Shanghai Inc - to Make Available to CEO Loan in Principal Amount of RMB13.7 Mln
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
Tiger Newspress  ·  02-10
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
IMMUNEONCO-B (01541) Rises Over 5% as Core Product IMM01 Expected to Submit pre-BLA Application by Year-End
Stock News  ·  01-22
IMMUNEONCO-B (01541) Rises Over 5% as Core Product IMM01 Expected to Submit pre-BLA Application by Year-End
ImmuneOnco (1541) Announces Phase III Clinical Trial Enrollment Progress for Timdarpacept
Bulletin Express  ·  01-21
ImmuneOnco (1541) Announces Phase III Clinical Trial Enrollment Progress for Timdarpacept
IMMUNEONCO-B (01541): Business Operations and Clinical Development Maintain Normalcy
Stock News  ·  01-21
IMMUNEONCO-B (01541): Business Operations and Clinical Development Maintain Normalcy
ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment
Reuters  ·  01-21
ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment
Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 10% in Morning Trading as IMM01 Receives Approval for Clinical Trial in Atherosclerosis Treatment
Stock News  ·  01-13
Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 10% in Morning Trading as IMM01 Receives Approval for Clinical Trial in Atherosclerosis Treatment
IMMUNEONCO-B (01541) Receives NMPA Approval for IMM01 (Tidapaxic) Clinical Trial in Atherosclerosis Treatment
Stock News  ·  01-12
IMMUNEONCO-B (01541) Receives NMPA Approval for IMM01 (Tidapaxic) Clinical Trial in Atherosclerosis Treatment
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for IMM01 Clinical Trial for Atherosclerosis
Reuters  ·  01-12
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for IMM01 Clinical Trial for Atherosclerosis
ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa China for Clinical Trial of Imm01 (Timdarpacept) for Atherosclerosis
THOMSON REUTERS  ·  01-12
ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa China for Clinical Trial of Imm01 (Timdarpacept) for Atherosclerosis
Guoyuan International: IMMUNEONCO-B (01541) Regains Global Rights to IMM2510, Overseas R&D Expected to Accelerate
Stock News  ·  01-08
Guoyuan International: IMMUNEONCO-B (01541) Regains Global Rights to IMM2510, Overseas R&D Expected to Accelerate
ImmuneOnco Regains Global Rights to Two Anti-tumor Medicines
MT Newswires Live  ·  01-07
ImmuneOnco Regains Global Rights to Two Anti-tumor Medicines
While institutions invested in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) benefited from last week's 10% gain, individual investors stood to gain the most
Simply Wall St.  ·  01-07
While institutions invested in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) benefited from last week's 10% gain, individual investors stood to gain the most
Recovering Overseas Rights, IMMUNEONCO-B (01541) Strategic Adjustment Opens New Opportunities
Stock News  ·  01-07
Recovering Overseas Rights, IMMUNEONCO-B (01541) Strategic Adjustment Opens New Opportunities
BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Immuneonco To Regain Global Rights- To IMM2510, IMM27M
Reuters  ·  01-06
BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Immuneonco To Regain Global Rights- To IMM2510, IMM27M
IMMUNEONCO-B (01541) Regains Global Rights to IMM2510 and IMM27M
Stock News  ·  01-06
IMMUNEONCO-B (01541) Regains Global Rights to IMM2510 and IMM27M
ImmuneOnco Biopharmaceuticals Shanghai Inc - ImmuneOnco to Regain Global Rights- to Imm2510 and Imm27m
THOMSON REUTERS  ·  01-06
ImmuneOnco Biopharmaceuticals Shanghai Inc - ImmuneOnco to Regain Global Rights- to Imm2510 and Imm27m
HK Stock Movement | IMMUNEONCO-B (01541) Rises Nearly 4% as IND Application for Self-Developed Amurelifusp-α Subcutaneous Formulation IMM0306S Accepted
Stock News  ·  2025-12-19
HK Stock Movement | IMMUNEONCO-B (01541) Rises Nearly 4% as IND Application for Self-Developed Amurelifusp-α Subcutaneous Formulation IMM0306S Accepted

Introduction

Company Name.
IMMUNEONCO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company's core product IMM01 is an innovative CD47-targeted molecule. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--